Organisation paid for research Program year 2025 Source: CMS Open Payments

Quantum Clinical Trials LLC

Neither a doctor nor a teaching hospital

Research payments

$2,974,307

152 payments

Through program year 2025, Quantum Clinical Trials LLC is reported as receiving $2,974,307 in research payments, across 152 payments.

By program year

4 rows
Year Kind Amount Payments
2025 Research $524,335 38
2024 Research $796,306 42
2023 Research $837,394 65
2022 Research $816,272 7

Breakdown

Who paid Research payments · program years 2022–2025
  1. Organon LLC $1,742,432 63 payments
  2. Sumitomo Pharma America, Inc. $629,489 31 payments
  3. Indivior Inc. $434,590 30 payments
  4. Novavax Inc $131,716 20 payments
  5. Idorsia Pharmaceuticals US Inc $36,080 8 payments
Studies the money was for Research payments · program years 2022–2025
  1. Og-8175A-023 $1,071,595 9 payments
  2. Og-8175A-023 $670,837 54 payments
  3. A Phase II Double Blind, Placebo Controlled, Randomised, Dose-Ranging Study to Assess the Safety and Efficacy of Indv-2000 Over 3 Months in Treatment Seeking Individuals With Opioid Use Disorder $434,590 30 payments
  4. A Phase 3 Singlearm Openlabel Study to Evaluate the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids Or Endometriosis Who Are 18 to 50 Years of Age and at Risk for Pregnancy $394,187 13 payments
  5. Serene $136,075 7 payments
  6. A Phase 2/3 Open-Label Study to Evaluate the Safety and Immunogenicity of an XBB.1.5 (Omicron Subvariant) SARS CoV-2 rS Vaccine Booster Dose in Previously mRNA COVID 19 Vaccinated and Baseline SARS CoV 2 Seropositive COVID-19 Vaccine Naïve Participants $110,716 19 payments
  7. A Phase 3, Single-Arm, Open-Label Study to Evaluate the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are 18 to 50 Years of Age and at Risk for Pregnancy $89,746 8 payments
  8. A Multi-center, Double-blind, Randomized, Placebo-controlled, 2-way Cross-over Post Approval Study to Investigate the Efficacy of Daridorexant in Subjects With Insomnia and Comorbid Nocturia $36,080 8 payments
  9. A Phase 2/3 Open-Label Study to Evaluate the Safety and Immunogenicity of an XBB.1.5 (Omicron Subvariant) SARS CoV-2 rS Vaccine Booster Dose in Previously mRNA COVID 19 Vaccinated and Baseline SARS CoV 2 Seropositive COVID-19 Vaccine Naive Participants $21,000 1 payment
  10. A Phase 3, Single-Arm, Open-Label Study to Evaluate the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are 18 to 50 Years of Age and at Risk for Pregnancy $9,481 3 payments
What the money was spent on Research payments · program years 2022–2025
  1. Patient care $1,742,432 63 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record